RxDoctor Payments Data

Kayhan Bangash, MD

Family Medicine · Madera, CANPI 1285071894

Payments from drug & device makers

$1,064in general payments, 2019–2025

Across 65 payments — averaging $16.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$474
  • AstraZeneca$169
  • GSK$133
  • Mannkind Corporation$71
  • Exact Sciences$52
  • Lilly USA, LLC$44
  • plus $121 from 6 others

What the payments were for

  • Food & beverage$1,02296%
  • Education$434%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,064 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$90,263
Medicare patients
207
Services billed
798

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin95$123,420
OzempicSemaglutide82$91,562
JanuviaSitagliptin Phosphate49$65,676
TradjentaLinagliptin42$40,148
EliquisApixaban22$35,207
XareltoRivaroxaban21$30,807
InvokanaCanagliflozin18$28,245
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$24,721
MyrbetriqMirabegron14$8,576
Atorvastatin Calcium595$8,043
Lantus SolostarInsulin Glargine,hum.Rec.Anlog53$6,175
Novolog FlexpenInsulin Aspart28$5,869
Albuterol Sulfate HfaAlbuterol Sulfate131$5,282
Levothyroxine Sodium346$4,763
Humalog Kwikpen U-100Insulin Lispro18$3,381

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$16$163,569137 claims
Novo NordiskOzempic$474$91,56282 claims
PfizerEliquis$18$35,20722 claims
GSKTrelegy Ellipta$133$24,72118 claims
Lilly USA, LLCHumalog$44$1,62513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Madera

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →